(RTTNews) - Tempus AI, Inc. (TEM) announced that its wholly owned subsidiary, Ambry Genetics, has launched GenomeNext and GenomeReveal, a comprehensive whole genome sequencing solution designed to improve diagnosis for patients with rare diseases.

Tempus AI's Ambry Genetics Launches GenomeNext To Improve Rare Disease Diagnosis 

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Hertz Global Holdings Inc (Symbol: HTZ), where a total of 113,948 contracts have traded so far, representing approximately 11.4 million underlying shares.  That amounts t

Noteworthy Tuesday Option Activity: HTZ, TEM, OKLO

(RTTNews) - The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic deals and corporate activity. Key updates spanned oncology, rare diseases, cardiov

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data 

Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth rate of 23.22%. Active Companies from around the markets with current developments this week include: MindWalk Holdings Corp. (NASDAQ: HYFT), AbCellera Biologics Inc. (NASDAQ: ABCL), Eli Lilly and Company (NYSE: LLY), Twist Bioscience Corporation (NASDAQ: TWST) and Tempus AI, Inc. (NASDAQ: TEM).

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

CHICAGO, October 01, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid.

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

Insider reported a trade at Tempus AI, Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Tempus AI, Inc. News